Clinical Trials Browser

Withdrawn × afuresertib × Clear all

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

Phase 1 Withdrawn

Neoplasms